MedTrace Logo

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

NCT00089583 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2017-03-07

Study results available
· View outcomes & findings →

Summary

This is a 48-week study to collect information on the safety and activity of an investigational medicine in patients, ages 2 to 18 years old, with HIV infection .

Conditions

  • Infection, Human Immunodeficiency Virus I

Interventions

DRUG

LEXIVA (GW433908)

Fosamprenavir suspension or tablet bid

DRUG

Ritonavir

Ritonavir solution bid

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2011-03-31
Completion
2013-07-31

Countries

  • United States
  • Belgium
  • Canada
  • Romania
  • Russia
  • South Africa
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089583 on ClinicalTrials.gov